In EXPAND study, the efficacy and safety of Ivacaftor alone or in combination with Tezacaftor were evaluated in CF patients 12 years of age or older heterozygous for F508del mutation and a RF-CFTR mutation [58]. Here, CFTR is linked to cystic fibrosis.